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MENDELIAN RANDOMIZATION
Genetically Predicted Blood Pressure and Risk of 
Atrial Fibrillation
Matthew C. Hyman ,* Michael G. Levin ,* Dipender Gill, Venexia M. Walker, Marios K. Georgakis , Neil M. Davies,  
Francis E. Marchlinski , Scott M. Damrauer
ABSTRACT: Observational studies have shown an association between hypertension and atrial fibrillation (AF). Aggressive 
blood pressure management in patients with known AF reduces overall arrhythmia burden, but it remains unclear whether 
hypertension is causative for AF. To address this question, this study explored the relationship between genetic predictors of 
blood pressure and risk of AF. We secondarily explored the relationship between genetically proxied use of antihypertensive 
drugs and risk of AF. Two-sample Mendelian randomization was performed using an inverse-variance weighted meta-analysis 
with weighted median Mendelian randomization and Egger intercept tests performed as sensitivity analyses. Summary 
statistics for systolic blood pressure, diastolic blood pressure, and pulse pressure were obtained from the International 
Consortium of Blood Pressure and the UK Biobank discovery analysis and AF from the 2018 Atrial Fibrillation Genetics 
Consortium multiethnic genome-wide association studies. Increases in genetically proxied systolic blood pressure, diastolic 
blood pressure, or pulse pressure by 10 mm Hg were associated with increased odds of AF (systolic blood pressure: odds 
ratio [OR], 1.17 [95% CI, 1.11–1.22]; P=1×10−11; diastolic blood pressure: OR, 1.25 [95% CI, 1.16–1.35]; P=3×10−8; pulse 
pressure: OR, 1.1 [95% CI, 1.0–1.2]; P=0.05). Decreases in systolic blood pressure by 10 mm Hg estimated by genetic 
proxies of antihypertensive medications showed calcium channel blockers (OR, 0.66 [95% CI, 0.57–0.76]; P=8×10−9) and 
β-blockers (OR, 0.61 [95% CI, 0.46–0.81]; P=6×10−4) decreased the risk of AF. Blood pressure–increasing genetic variants 
were associated with increased risk of AF, consistent with a causal relationship between blood pressure and AF. These data 
support the concept that blood pressure reduction with calcium channel blockade or β-blockade could reduce the risk of AF. 
(Hypertension. 2021;77:376–382. DOI: 10.1161/HYPERTENSIONAHA.120.16191.) • Data Supplement
Key Words: atrial fibrillation ◼ blood pressure ◼ calcium channel blockers ◼ hypertension
Atrial fibrillation (AF) remains a leading contributor to cardiovascular morbidity and mortality worldwide.1,2 Observational studies have demonstrated an asso-
ciation between modifiable risk factors—specifically 
hypertension, obesity, alcohol consumption, and obstruc-
tive sleep apnea—and arrhythmic burden of patients with 
known AF.3 Although linked observationally, it is unclear 
whether modification of these risk factors may prevent 
new-onset AF.
Due to its high prevalence, hypertension is thought 
to be the single greatest contributor to the burden 
of AF. In population studies such as the Framingham 
Heart Study and Atherosclerosis Risk in Communities 
Study, up to 20% of AF cases are attributed to pre-
existing hypertension.4,5 Furthermore, 60% to 80% of 
patients with known AF have comorbid hypertension.6 
Despite these observations, initiation of blood pres-
sure–lowering therapy was not associated with a clear 
reduction in AF burden in the Framingham cohort.7 
Similarly, a randomized comparison of the angiotensin-
converting enzyme inhibitor, ramipril, versus placebo 
failed to demonstrate a relationship between ramipril 
therapy and incident AF.8 Secondary analyses in other 
studies comparing hypertensive agents (angiotensin-
converting enzyme inhibitors, β-blockers [BBs], cal-
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not demonstrated a consistent benefit of one antihy-
pertensive regimen over another for reducing AF.9–11 
Comparisons of intensive blood pressure lowering with 
standard blood pressure lowering have suggested a 
benefit for patients with hypertension and elevated 
risk of cardiovascular events but not hypertension and 
diabetes.12,13 The inconsistent findings of antihyperten-
sive therapy studies and observational studies have led 
some to question the strength of the direct relation-
ship between blood pressure and AF or argue that it is 
driven by isolated subpopulations.14–17
Preventative studies on a population scale are dif-
ficult to accomplish in a randomized and adequately 
powered fashion with sufficient duration. To overcome 
this limitation, this study used a population genetics–
based approach within a Mendelian randomization 
(MR) framework to better understand the causal role of 
blood pressure on the risk of AF. This technique takes 
advantage of the random allocation of blood pressure–
associated genetic variants that occurs at conception. 
This random assortment minimizes the chance of envi-
ronmental confounding, enabling investigation into the 
causal relationship between blood pressure and AF. 
We subsequently evaluated genetic proxies for the 
pathways targeted by antihypertensive medications to 
better understand potential class effects of antihyper-
tensive medications on AF.
METHODS
The authors declare that all supporting data are available within 
the article and its Data Supplement.
Study Populations
For the primary analysis, summary-level data for genome-wide 
association studies (GWAS) of hypertension and AF were 
used.18,19 Blood pressure data were obtained from the 2018 
Evangelou et al International Consortium for Blood Pressure+UK 
Biobank GWAS meta-analysis, which included systolic blood pres-
sure (SBP), diastolic blood pressure (DBP), and pulse pressure 
(PP) measurements in up to 757 601 individuals. Summary statis-
tics for blood pressure are publicly available and were downloaded 
from the National Heart, Lung, and Blood Institute Genome-Wide 
Repository of Associations Between SNPs and Phenotypes cata-
log (https://grasp.nhlbi.nih.gov/FullResults.aspx). AF data (atrial 
flutter, paroxysmal AF, and persistent AF grouped together) were 
obtained from the 2018 Roselli et al AF GWAS meta-analysis 
from the AFGen (Atrial Fibrillation Genetics) consortium study, 
including 65 446 AF cases and 522 744 controls. Summary sta-
tistics for AF were contributed by the AFGen consortium (http://
afgen.org), are publicly available, and may be downloaded from 
the Variant to Function Knowledge Portal (http://www.kp4cd.org/
datasets/v2f). Because both the blood pressure exposure and 
AF outcome studies included participants from the UK Biobank 
(458 577 for BP and 351 017 for AF), bias due to sample over-
lap was estimated using a previously described tool, available at 
https://sb452.shinyapps.io/overlap.20 Across all ranges of sample 
overlap (0%–100%), there was no substantial inflation in type I 
error rate or bias (eg, for an observational odds ratio [OR] of 1.6 
per 10-mm Hg increase in SBP with 100% exposure-outcome 
sample overlap, type I error remained 0.05, with bias of 0.0007).
Study Exposures
The 2018 Evangelou et al International Consortium for Blood 
Pressure+UK Biobank discovery meta-analysis GWAS included 
up to 757 601 participants. This analysis included up to 299 024 
European participants from 77 independent studies genotyped 
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
AFGen Atrial Fibrillation Genetics
BB β-blocker
CCB calcium channel blocker
DBP diastolic blood pressure









• In this Mendelian randomization study involving sum-
mary data from >990 000 individuals, genetically pre-
dicted 10-mm Hg increases in blood pressure were 
associated with increased risk of atrial fibrillation (17% 
for systolic blood pressure and 25% for diastolic blood 
pressure).
What Is Relevant?
• Analyses using genetic proxies for antihypertensive 
medications suggest that calcium channel blocker and 
β-blocker therapy may be effective in preventing atrial 
fibrillation.
Summary
On a population level, blood pressure lowering may 
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with various arrays and imputed to either the 1000 Genomes 
Reference Panel or the HRC platforms and 458 577 partici-
pants from the UK Biobank. Blood pressure ascertainment varied 
among cohorts, and study-specific details are presented in the 
Data Supplement.18 For each BP trait, genetic variants associated 
with SBP, DBP, and PP at genome-wide significance (P<5×10−8) 
were identified and linkage disequilibrium pruned using the default 
settings of the clump_data function of the TwoSampleMR pack-
age (distance threshold, 10 000 kb; r2<0.001) using the 1000 
Genomes European ancestry reference panel to identify indepen-
dent variants. Because the Evangelou et al21 study adjusted effect 
estimates for body mass index potentially leading to introduction 
of collider bias as body mass index is causal for both elevated 
blood pressure and AF, a sensitivity analysis was performed using 
systolic (n=436 419) and diastolic (n=436 424) blood pressure 
GWAS summary statistics from European UK Biobank participants 
adjusted for genotyping array, age, sex, and population structure.21
Primary Outcome
The AFGen consortium identified participants from >50 stud-
ies (84.2% European, 12.5% Japanese, 2% African American, 
and 1.3% Brazilian and Hispanic), including participants from 
the UK Biobank, Biobank Japan, other international biobanks, 
and international cardiovascular cohort studies (adjusted for 
age, sex, and study-specific covariates). AF ascertainment was 
study specific, including diagnostic codes, electronic health 
record information, and self-report.
Study Design
The primary analysis estimated the effect of blood pressure 
on the risk of AF using 2-sample MR with an inverse-variance 
weighted model with random effects. The MR-Egger bias 
intercept test was used to identify the presence of bias from 
directional pleiotropy. Sensitivity analysis was performed using 
weighted median MR and Egger intercept tests, which are 
more robust to the presence of invalid genetic instruments.22
Recent work has demonstrated that genetic proxies can be 
used to estimate the effect of individual antihypertensive drug 
classes on clinical outcomes using an MR framework.23,24 We 
used 2 approaches to estimate the effect of blood pressure–
lowering medication on risk of AF:
1. Genes encoding the targets of antihypertensive medi-
cations (angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, BBs, CCBs, and thia-
zide diuretic agents) were identified using DrugBank 
and the GeneHancer database in the GeneCards plat-
form (v4.7).23 Single-nucleotide polymorphisms (SNPs) 
were identified within corresponding genes, promoter 
regions, or enhancers that were associated with SBP in 
the 2018 UK Biobank and International Consortium of 
Blood Pressure GWAS meta-analysis at genome-wide 
significance (P<5×10−8) and clumped to a linkage dis-
equilibrium threshold of r2<0.1 using the 1000 Genomes 
European reference panel. These genetic variants were 
used as instruments to model the effect of lower SBP 
mediated by individual antihypertensive drug classes. The 
SNPs were then utilized to estimate the effect of the 
individual antihypertensive drug classes on the risk of AF 
using 2-sample inverse-variance weighted and median 
weighted MR as above.
2. Expression quantitative trait loci for protein targets of 
antihypertensive medications were used as a proxy for 
the action of a drug on its target (eg, variants associated 
with angiotensin-converting enzyme gene expression as a 
proxy for the angiotensin-converting enzyme inhibitor drug 
class).24 Twelve antihypertensive drug classes were consid-
ered: adrenergic neuron blocking drugs; α-adrenoceptor 
blockers, angiotensin-converting enzyme inhibitors, angio-
tensin-II receptor blockers, β-adrenoceptor blockers, CCBs, 
centrally acting antihypertensive drugs, loop diuretics; 
potassium-sparing diuretics and aldosterone antagonists, 
renin inhibitors, thiazides and related diuretics, and vasodi-
lator antihypertensives. SNPs were identified for the pro-
tein targets of each drug class using the Genotype-Tissue 
Expression project data (release V7; dbGaP accession 
phs000424.v7.p2), which contain expression quantitative 
trait loci analyses of 48 tissues in 620 donors.25 SNPs 
defined by Genotype-Tissue Expression as the variant with 
the smallest nominal P for a variant-gene pair were selected 
for analysis and validated as instruments by estimating their 
effect on SBP using 2-sample MR. Expression quantitative 
trait loci with evidence of a significant effect on SBP by 
gene expression MR (P<0.05) were used for the analysis.
Statistical Analysis
Two-sample MR was performed using the TwoSampleMR 
package in R (https://github.com/MRCIEU/TwoSampleMR).26 
Variants associated with each blood pressure exposure at 
genome-wide significance (P<5×10−8) were harmonized with 
the variants from the AF GWAS19 and linkage disequilibrium 
clumped (distance threshold, 10 000 kb; r2=0.001) using the 
1000 Genomes European ancestry reference panel, iden-
tifying a final set of independent SNPs to use as a genetic 
instrument for blood pressure. The exposure-outcome asso-
ciation was calculated for each variant independently; inverse-
variance weighted 2-sample MR with random effects was 
used as the primary analysis with a weighted median analy-
sis performed as a sensitivity analysis.27 For each variant 
included in the genetic instruments, the proportion of vari-
ance (R2) in the phenotype explained was calculated using the 
formula R =
2 MAF(1 MAF)






−( ) − (where 
MAF represents the effect allele frequency, β represents 
the effect estimate of the genetic variant in the exposure 
GWAS, se represents the SE of effect size for the genetic 
variant, and N represents the sample size).28 F statistics 








 to assess the strength of the selected instruments.29 
Changes in blood pressure were expressed in terms of a 
10-mm Hg increment as it was viewed as a clinically relat-
able target for blood pressure modification. All statisti-
cal analyses were performed using R, version 3.6.2.31.
RESULTS
Association of Blood Pressure With AF
We identified a set of independent variants to serve as 
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(n=347), which accounted for 4.0%, 4.2%, and 3.6% of 
the measured variability in these exposures, respectively 
(Tables S1 through S3 in the Data Supplement). For the 
SBP instrument, the mean F statistic was 75 (range, 
30.4–645.7). For the DBP instrument, the mean F sta-
tistic was 79.9 (range, 30–846.6). For the PP instrument, 
the mean F statistic was 76.4 (range, 30.4–627.9). Bias 
due to sample overlap from the UK Biobank participants 
included in both the blood pressure exposure GWAS 
and AF outcome GWAS was estimated to be negligible 
across a range of observational effect sizes: for exam-
ple, at 100% sample overlap, bias was estimated to be 
0.0003 for an observational OR of 1.3 and 0.00069 for 
an observational OR of 1.6 (Table S4).
Two-sample MR using the above genetic instruments 
and inverse-variance weighted modeling demonstrated 
that each 10-mm Hg genetically predicted increase in 
SBP, DBP, and PP increased the risk of AF (SBP: OR, 
1.17 [95% CI, 1.11–1.22]; P=1×10−11; DBP: OR, 1.25 
[95% CI, 1.16–1.35]; P=3×10−8; PP: OR, 1.1 [95% CI, 
1.0–1.2]; P=0.05; Figure 1). Results were similar in a 
sensitivity analysis using the weighted median method, 
with increased SBP, DBP, and PP increasing the risk of 
AF (SBP: OR, 1.18 [95% CI, 1.12–1.23]; P=5×10−11; 
DBP: OR, 1.24 [95% CI, 1.14–1.34]; P=4×10−7; PP: OR, 
1.11 [95% CI, 1.02–1.2]; P=0.01; Figure 1). The effects 
of SBP and DBP on the risk of AF were also similar 
using alternative genetic instruments derived from the 
UK Biobank, which were not corrected for body mass 
index (Figure S1).
Genetically Proxied Blood Pressure Reduction 
Through Antihypertensive Drug Targets and AF
To estimate the effect of blood pressure reduction by 
different classes of antihypertensive medications, we 
identified common genetic variants located within genes 
of protein targets of CCBs and BBs, as described 
previously.23 Twenty independent variants within pro-
tein targets of CCBs and 5 independent variants within 
protein targets of BBs were associated with SBP at 
genome-wide significance (Table S5). When using these 
genetic proxies to estimate the effect of each 10-mm Hg 
decrease in SBP by each antihypertensive drug class, 
genetically predicted protein targets of CCBs and BBs 
were associated with lower risk of AF (CCB: OR, 0.66 
[95% CI, 0.57–0.76]; P=8×10−9; BB: OR, 0.61 [95% CI, 
0.46–0.81]; P=6×10−4; Figure 2). In a complimentary 
analysis, we used expression quantitative trait loci for 
the protein targets of antihypertensive medications given 
genetic variants may exert their action via distant interac-
tions (rather than via a true cis-acting association; Table 
S6).24 Using this technique, antihypertensive medication 
proxies reduced the risk of AF (CCB: SNP, n=23; OR, 
0.66 [95% CI, 0.57–0.76]; P=8×10−9; BB: SNP, n=10; 
OR, 0.61 [95% CI, 0.46–0.81]; P=6×10−4). There was 
no strong evidence of effect of other antihypertensive 
medication classes on AF risk (Table S7).
DISCUSSION
This study utilized MR to leverage population-level 
genetic information to explore the causal relationship 
between blood pressure and AF. The genetic determi-
nants of elevated SBP and DBP were found to strongly 
associate with the risk of AF—an association that per-
sisted in statistical sensitivity analyses more robust to 
the inclusion of pleiotropic variants. Previously validated 
genetic proxies for the therapeutic effects of antihyper-
tensive drug classes were used to estimate the impact of 
individual antihypertensive drug classes on incident AF, 
suggesting a potential role for antihypertensive medica-
tions in prevention.
A relationship between hypertension and AF has 
previously been established in observational analyses.4,5 
These findings, however, were limited in demonstrating 
Figure 1. Genetic proxies of blood pressure and risk of atrial fibrillation.
A, Two-sample Mendelian randomization using an inverse-variance weighted model was created using a genetic instrument associated with a 
10-mm Hg increase in systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) and risk of atrial fibrillation. B, 
A median weighted model was created as a sensitivity analysis. Figures are expressed as odds ratios (ORs), 95% CIs, and P for Mendelian 
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a causal role for hypertension in the development of 
AF due to the potential of residual confounding and 
reverse causation.14 This study sought to mitigate this 
risk of confounding by using genetic instruments ran-
domly assorted in the population to proxy the effect of 
increased blood pressure traits on the risk of AF. In doing 
so, we found that genetically proxied increases in SBP 
and DBP were associated with increased risk of AF. 
These elevated blood pressure effects are directionally 
similar to those identified in observational studies.30 In 
this analysis, PP was not as strongly associated with the 
risk of AF as SBP and DBP changes. As PP is depen-
dent upon systolic and diastolic pressure, our data would 
suggest that the relative magnitude of each independent 
blood pressure parameter is more predictive than the 
relationship between the two. There are 2 prior studies 
looking at blood pressure genetics and AF; both of which 
are complimentary to the current study. The first was an 
MR analysis using an SBP polygenic risk score derived 
from an older blood pressure GWAS.31 The second used 
a less exhaustive set of blood pressure–related SNPS 
to demonstrate that SBP and DBP mediate ischemic 
stroke risk, in part, through AF.32
A variety of mechanisms have been proposed to 
explain how hypertension contributes to the risk of AF. 
Animal models of hypertension have demonstrated the 
presence of left atrial scaring and inflammation.33–35 This 
scaring and fibrosis is thought to create altered patterns 
of conduction and functional slowing, allowing for the 
development and perpetuation of AF triggers.34,36 Con-
cordantly, hypertensive animals have greater heteroge-
neity of atrial activation with increased susceptibility to 
AF induction.34 Other manifestations of left atrial remod-
eling such as increased left atrial size have been associ-
ated with hypertension and elevated SBP in particular.37 
It should be noted, however, that the impact of hyperten-
sion on AF risk persists after adjustment for left atrial 
size and mass.30
Beyond mechanism, this study explores the question 
of whether pharmacological intervention may meaning-
fully impact a patient’s risk of AF. While it would be ethi-
cally difficult to fully withhold antihypertensive therapy 
in a randomized trial, we leveraged genetic proxies to 
explore the impact of individual antihypertensive drug 
classes. Our study suggests that both CCBs and BBs 
can significantly mitigate a patient’s risk of developing 
AF. While it is tempting to compare the results of our 
genetic study with human pharmacological studies, there 
are inherent differences in these two approaches. Our 
analysis used genetic proxies to model antihypertensive 
class effects and reflects a lifetime of genetic exposure. 
By contrast, antihypertensive drug trials estimate the 
effect of only a limited duration of antihypertensive ther-
apy initiated later in a patient’s life. It should be noted that 
while other drug classes like angiotensin receptor block-
ers did not demonstrate a significant AF-reducing effect 
in our study, we may have been underpowered to detect 
a relationship between the two due to a lack of robust 
genetic instruments. While it is possible that certain anti-
hypertensive drug classes have more of an AF-reducing 
effect than others, our analysis is not able to fully tease 
out this question. It should be further noted that clinical 
trials and case-control analyses have not found BBs and 
CCBs to be consistently superior to other drug classes 
including angiotensin receptor blockers and angiotensin-
converting enzyme inhibitors when examining impact on 
AF burden.10,11,38
A final point should be made that while the effect size 
of a blood pressure increase on AF was smaller in mag-
nitude than the effect size of CCB and BB drug therapy 
on AF, this discrepancy may be partially explained by a 
nonlinear or heterogenous relationship between blood 
pressure reductions and blood pressure increases. The 
difference in effect size may also be due to the pleiotro-
pic effects of these particular antihypertensive medica-
tions as β-receptor signaling and calcium handling have 
Figure 2. Genetic proxies of antihypertensive medications and atrial fibrillation risk.
Two-sample Mendelian randomization was performed using genetic proxies for 10-mm Hg systolic blood pressure lowering by individual 
antihypertensive medication classes: (A) β-blockers and (B) calcium channel blockers. Inverse-variance weighted and median weighted models 
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both been implicated in AF initiation and arrhythmogen-
esis independent of blood pressure.
Limitations
First, while the GWAS of AF was multiethnic, the study 
was enriched with individuals of European ancestry as 
was the GWAS of blood pressure traits. This may have 
skewed the risk estimates in our findings, and as such, 
the analysis should be repeated in other populations 
before being generalized across ethnic groups. Second, 
this analysis estimates the lifelong effects of genetically 
predicted blood pressure reduction on AF risk and does 
not directly investigate the effects of shorter term altera-
tions in blood pressure such as through pharmacological 
treatment in adulthood. Third, it should be noted that the 
risk reduction of CCBs and BBs was quantified in terms 
of 10-mm Hg blood pressure increments, which assumes 
a linear relationship. However, this study cannot answer 
the question of what level of blood pressure reduction 
maximizes AF risk reduction.
Conclusions
Blood pressure–increasing genetic variants were asso-
ciated with an increased risk of AF, consistent with a 
causal relationship between blood pressure and AF. 
These data support the concept that blood pressure 
reduction through pharmacological intervention and spe-
cifically calcium channel blockade or β-blockade could 
reduce the risk of AF.
Perspectives
From a public health perspective, early interventions to 
limit lifetime exposure to elevations in SBP and DBP 
could have tremendous impact on the prevalence of AF. 
Furthermore, initiatives targeting known AF risk factors 
like hypertension and obesity may be key to reducing AF 
at a population level.
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